Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer

Phase 2

Completed

Interventions: Radiation: Arm 1 stereotactic body radiation therapy
Radiation: Arm II stereotactic body radiation therapy

Brief Summary: RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. It is not yet known which regimen of radiation therapy is more effective in treating patients with non-small cell lung cancer.

PURPOSE: This randomized phase II trial is studying the side effects of two radiation therapy regimens and to see how well they work in treating patients with stage I or stage II non-small cell lung cancer.

Detailed Description: OBJECTIVES:

Primary

* To compare the incidence of toxicity with two established stereotactic body radiotherapy (SBRT) regimens in patients with node-negative, peripheral stage I or II non-small cell lung cancer.

Secondary

* To compare quality of life, patterns of failure, disease-free survival, and overall survival of these patients after treatment with one of two established SBRT regimens.

* To correlate outcomes and toxicities with imaging and patient and tumor biomarkers.

OUTLINE: Patients are stratified according to Karnofsky performance status and treatment center. Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients undergo 1 high-dose fraction of stereotactic body radiotherapy (SBRT).

* Arm II: Patients undergo 3 high-dose fractions (approximately 1 week apart) of SBRT.

Quality of life is assessed periodically by the EORTC QLQ-C30 and -LC13 questionnaires

Blood and tissue samples may be collected periodically and examined for biomarkers via ELISA and immunoblotting.

After completion of study treatment, patients are followed for 5 years.

Recruitment & Eligibility

Inclusion Criteria

Histologically confirmed non-small cell lung cancer
T1-T2, N0 disease measuring ≤ 5 cm( T3 tumor based on chest wall involvement is Excluded)
Surgically resectable primary disease, however patient evaluated by thoracic oncologist and deemed medically inoperable OR patient refuses surgical resection
Age >= 18

Exclusion Criteria

Prior thoracic radiation therapy
T2 or T3 tumor greater than 5 cm or T3 tumor based on chest wall involvement
Node positive or metastatic disease
Tumor location within the zone of the proximal bronchial tree. The proximal bronchial tree is defined as the carina, right and left main bronchi, right and left upper lobe bronchi, bronchus intermedius, right middle lobe bronchus, lingular bronchus, and right and left lower lobe bronchi. The zone of the proximal bronchial tree is defined as a volume 2cm in all directions around the proximal bronchial tree.
No other conditions deemed by the PI or associates to make the patient ineligible for protocol investigations, procedures, and high-dose external beam radiotherapy (e.g., unable to lie still and breathe reproducibly)
Pregnant or unwilling to use adequate contraception

Arm && Interventions

Group	Intervention	Description
Arm I	Arm 1 stereotactic body radiation therapy	Patients undergo 1 high-dose fraction of stereotactic body radiotherapy (SBRT).
Arm II	Arm II stereotactic body radiation therapy	Patients undergo 3 high-dose fractions (approximately 1 week apart) of SBRT.

Primary Outcome Measures

Name	Time	Method
Overall Survival	5 years	Median overall survival
Correlation Between Blood and Serum Markers and Survival and Toxicity	4 years
Incidence of AE Grade 3 or Higher Toxicity	1year	Count of patients experiencing at least one grade 3 or higher adverse event. The Common Terminology Criteria for Adverse Events (CTCAE) v3.0 is used for assessing the adverse events. High grades AEs are considered worse.

Secondary Outcome Measures

Name	Time	Method

Locations (3): SUNY Upstate Medical University
🇺🇸
Syracuse, New York, United States
Cleveland Clinic
🇺🇸
Cleveland, Ohio, United States
Roswell Park Cancer Institute
🇺🇸
Buffalo, New York, United States